Abstract: Embodiments of this application disclose a method for detecting a terminal device in an idle state and a related device. The method includes: sending a first system message, where the first system message includes a first field, and the first field is used to indicate the terminal device in the idle state to periodically initiate random access; and receiving a random access request sent by the terminal device in the idle state, so that the terminal device in the idle state enters a connected state. The network device sends, to the terminal device, the first system message that carries the first field, and the terminal device in the idle state may periodically initiate random access to the network device, to connect the terminal device and the network device. The network device learns, in this way, whether a terminal device exists in a current coverage area.

Abstract: A method of evaluating an ability of a large language model (LLM) to generate an accurate hypothesis model (HM) of a linear programming word problem (LPWP) is provided. An attributed bipartite graph of the HM is transformed into an attributed bipartite graph of the ground truth model of the LPWP. The number of transformation steps required for the transformation effectively measures the ability of the LLM to generate an accurate HM. The use of attributed bipartite graphs provide invariance in the order to LPWP variables and constraints. Corresponding apparatus and systems are also provided.

Abstract: A data processing method includes: displaying a document source control in a target application; displaying a to-be-authorized-document list in response to a trigger operation on the document source control, the to-be-authorized-document list including one or more document titles, the one or more document titles including a title that is in a document application and that corresponds to document data associated with a first object, and the first object being logged in to the document application through the target application; and displaying a first authorized-document list including a first title in response to a trigger operation on the to-be-authorized-document list (S103), the first title being a triggered document title, and the target application having a permission to perform service processing on document data corresponding to the first title.

Abstract: An iron-carbon composite material, a preparation method therefor, and an application thereof related to microbial technology applications. The method includes the following steps: a cross-linking and curing step: carrying out cross-linking and curing to iron powder and biological activated carbon by using an alkaline earth metal salt and a cross-linking agent; and a mineralization treatment step: soaking the cross-linked and cured iron-carbon composite material in a mineralization bacteria solution for 5-15 min, and carrying out drying to obtain an iron-carbon composite material.

Abstract: A method includes receiving, from a user device associated with a user, a plurality of annotated documents. Each respective annotated document includes one or more fields and each respective field labeled by a respective annotation. The method includes, for a threshold number of iterations, randomly selecting a respective subset of annotated documents from the plurality of annotated documents; training a respective model on the respective subset of annotated documents; and generating, using the plurality of annotated documents not selected for the respective subset of annotated documents, a respective evaluation of the respective model. The method also includes providing, to the user device, each respective evaluation.

Abstract: A method for preventing and treating pollution plume migration of a permeable reactive barrier including: mounting monitoring assemblies, so as to monitor operation parameters of an active filler in a reactive barrier and a downstream water body of the reactive barrier in real time; determining whether the active filler in the reactive barrier is passivated according to a change state of the operation parameters, and if passivation occurs, performing a depassivation treatment on the reactive barrier; determining whether a gas blockage occurs in the active filler in the reactive barrier according to the change state of the operation parameters, and if a gas blockage occurs, performing a gas guiding treatment on the reactive barrier; and determining whether a microorganism content in the reactive barrier is greater than a preset microorganism value according to the change state of the operation parameters.

Abstract: A soft-bodied apparatus and a method for opening an eyelid are provided. The apparatus includes: a head support module, a real-time eyelid positioning module, a robot end-effector real-time positioning module, and an automatic eyelid opening operation module. The automatic eyelid opening operation module includes a robot body and a robot control system. The robot body is provided with a multi-axis rigid body mechanical arm and a soft-bodied end-effector. The robot control system takes the real-time poses of the upper and lower eyelids of the user as a motion target, and takes the real-time shape and the pose of the soft-bodied end-effector as feedback information to control motion of the robot body to automatically open the eyelid.

Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: Disclosed are novel solid forms of compound (I), (3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid), and pharmaceutical compositions comprising solid forms thereof having characteristics described herein, which can be used as a HBV capsid inhibitor (or HBV Core Protein Allosteric Modifier), or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: The present invention relates to novel solid forms of compound (I), 3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid and pharmaceutical compositions comprising solid forms thereof disclosed herein, which can be used as a HBV capsid inhibitor (or HBV Core Protein Allosteric Modifier), or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: The present invention relates to a cocrystal of progesterone, which is formed by the active ingredient progesterone and a cocrystal former which is selected from isophthalic acid, 4-formylbenzeneboronic acid and 3-nitrophthalic acid. The present invention also relates to the method for preparing the cocrystal of progesterone and use thereof for increasing the thickness of endometrium, improving progesterone's solubility or increasing progesterone's permeation rate.

Abstract: The invention relates to novel glutamine analogs, a composition containing the glutamine analogs and the use thereof.

Abstract: A pickup truck rack includes a fastening base, a support frame, a fastening rod, and a fastening frame. There are two fastening bases. One support frame is fastened on each of upper ends of the two fastening bases. Rail grooves are provided at both an upper end and a lower end of the fastening rod. The fastening frame and two support frames are respectively disposed at the upper end and lower end of the fastening rod and are reciprocable or fixable along the corresponding rail grooves. The support frame is a retractable support frame formed by an inner tube and an outer tube that are sleeved. A vertical sliding groove is opened on the inner tube. A clip is provided inside the sliding groove. A bolt through hole is provided at an upper end of the outer tube.

Abstract: A soft-bodied apparatus and a method for opening an eyelid are provided. The apparatus includes: a head support module, a real-time eyelid positioning module, a robot end-effector real-time positioning module, and an automatic eyelid opening operation module. The automatic eyelid opening operation module includes a robot body and a robot control system. The robot body is provided with a multi-axis rigid body mechanical arm and a soft-bodied end-effector. The robot control system takes the real-time poses of the upper and lower eyelids of the user as a motion target, and takes the real-time shape and the pose of the soft-bodied end-effector as feedback information to control motion of the robot body to automatically open the eyelid.

Abstract: A vehicle rack includes two cross beams, the cross beams being hollow square rods parallelly placed, the bottom center of the cross beam being provided with a sliding slot along the beams; two fixing rods, the fixing rods being hollow and each including an H-shaped reinforcing seat, the H-shaped reinforcing seat forming an upper sliding slot I on a top surface of the fixing rod and forming a lower sliding slot I on a bottom surface of the fixing rod, the fixing rods being particular to the two cross beams; a plurality of connecting seat, the connecting seats movably connecting the cross beams and the fixing rods, the connecting seats including upper bolt connecting parts; a plurality of supporting frames, the fixing rods each connecting two supporting frames, the supporting frames including lower bolt connecting parts.

Abstract: Embodiments of this application disclose a method for detecting a terminal device in an idle state and a related device. The method includes: sending a first system message, where the first system message includes a first field, and the first field is used to indicate the terminal device in the idle state to periodically initiate random access; and receiving a random access request sent by the terminal device in the idle state, so that the terminal device in the idle state enters a connected state. The network device sends, to the terminal device, the first system message that carries the first field, and the terminal device in the idle state may periodically initiate random access to the network device, to connect the terminal device and the network device. The network device learns, in this way, whether a terminal device exists in a current coverage area.

Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: The present invention relates to novel solid forms of compound (I) [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.